(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.92%.
Terns Pharmaceuticals's earnings in 2025 is -$94,435,000.On average, 14 Wall Street analysts forecast TERN's earnings for 2025 to be -$99,240,895, with the lowest TERN earnings forecast at -$99,844,429, and the highest TERN earnings forecast at -$95,529,608. On average, 14 Wall Street analysts forecast TERN's earnings for 2026 to be -$120,824,010, with the lowest TERN earnings forecast at -$130,651,714, and the highest TERN earnings forecast at -$105,933,822.
In 2027, TERN is forecast to generate -$141,758,551 in earnings, with the lowest earnings forecast at -$160,666,297 and the highest earnings forecast at -$127,688,090.